Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 11/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930523 | 0.83 | LRRK2 (0.37) | LRRK2MAP3K12 | |
| SCHEMBL5021286 | 0.83 | LRRK2 (0.37) | LRRK2MAP3K12 | |
| SCHEMBL17076721 | 0.83 | LRRK2 (0.37) | LRRK2MAP3K12 | |
| SCHEMBL26695891 | 0.81 | LRRK2 (0.49) | LRRK2DYRK1A | |
| SCHEMBL5021134 | 0.80 | DRD2 (0.35) | LRRK2MAP3K12 | |
| SCHEMBL5021291 | 0.79 | LRRK2 (0.33) | LRRK2 | |
| SCHEMBL15650712 | 0.79 | KAT2B (0.36) | LRRK2MAP3K12 | |
| SCHEMBL15649834 | 0.79 | KAT2B (0.36) | LRRK2MAP3K12 | |
| SCHEMBL15649835 | 0.79 | KAT2B (0.36) | LRRK2MAP3K12 | |
| SCHEMBL15651625 | 0.78 | LRRK2 (0.43) | LRRK2DYRK1AMAP3K12MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 142/4885MAP3K12 79/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 141/4885MAP3K12 90/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 142/4885MAP3K12 79/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 136/4885MAP3K12 67/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 136/4885MAP3K12 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.